Followers | 785 |
Posts | 128093 |
Boards Moderated | 9 |
Alias Born | 09/26/2011 |
Tuesday, May 29, 2012 2:11:13 PM
Herborium Group Investors Overview
http://www.herborium.com/Investor_Relations.html
Capitalizing on the increased trend for natural and organic products in Health Care, Food and Personal Care, Herborium Group Inc. offers what constitutes the complete natural medicinal solution. We are an industry innovator and our goal is to attract, educate and maintain high involvement clients in both commercial and consumer markets. Our mantra is the intense use of proprietary and superior natural medicinal products supported by the application of interactive and customized marketing strategies.
The Market potential for this sector worldwide is $250 billion and growing, with over $60 billion a year already spent in the USA in the natural and alternative health care sector.
Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce its products to Western Markets. These unique strategies mitigate risks, decrease development costs and speeds up time to market.
Herborium Group sells its products in the United States, the United Kingdom, Continental Europe and Asia through a network of distributors, clinics, specialty retailers, and via e-commerce. The number of distribution contracts and Letters of Intent are in the final stages of negotiations which cover Canada, Israel, Taiwan and other markets in Asia as well as additional distribution venues in the USA and EU.
Herborium has several products in the pipeline being prepared for the market in the areas of dermatology and women and men health, and additional products in development and testing to insure our continued ability to grow sales and provide our customers with superior products they need
Finally, Herborium’s strategy actually responds to new demands within the health care sector, and despite the current difficult economic times, the company aggressively and successfully pursues its financial strategy to secure the resources necessary to build consumer satisfaction and shareholder value.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM